Because of the rising variety of therapeutic monoclonal antibodies (mAbs) used within the clinic, there’s an rising want for sturdy analytical strategies to quantify complete mAb concentrations in human plasma for medical research and therapeutic drug monitoring.
We developed a simple, fast, and sturdy pattern preparation methodology for liquid chromatography-tandem mass spectrometry (LC-MS/MS) evaluation. The tactic was validated for infliximab (IFX), rituximab (RTX), cetuximab (CTX), dupilumab (DPL), dinutuximab (DNX), vedolizumab (VDZ), and emicizumab (EMZ). Saturated ammonium sulfate (AS) was used to precipitate immunoglobulins in human plasma.
After centrifugation, supernatant containing albumin was decanted, and the precipitated immunoglobulin fraction was re-dissolved in buffer containing 6M guanidine. This fraction was then utterly denatured, lowered, alkylated, and trypsin digested. Lastly, signature peptides from the seven mAbs had been concurrently quantified on LC-MS/MS along with their inside requirements secure isotopically labeled peptide counterparts.
The linear dynamic ranges (1 – 512 mg/L) of IFX, CTX, RTX, and EMZ confirmed wonderful (R2 > 0.999) linearity and people of DPL, DNX, and VDZ confirmed good (R2 > 0.995) linearity. The tactic was validated in accordance with the EMA tips. EDTA plasma, sodium citrate plasma, heparin plasma, and serum yielded comparable outcomes.
Ready samples had been secure at room temperature (20°C) and at 5°C for three days, and confirmed no decline in focus for all examined mAbs. This described methodology, which has the benefit of a simple, fast, and sturdy pre-analytical pattern preparation, can be utilized as a template to quantify different mAbs in human plasma or serum.
Reactions and COVID-19 illness development following SARS-CoV-2 monoclonal antibody infusion
SARS-CoV-2 monoclonal antibodies (mAbs) have been proposed as a remedy for gentle to average COVID-19, with favorable outcomes reported in medical trials and an emergency use authorization granted by the Meals and Drug Administration. Actual-world knowledge stay restricted, nevertheless, and thus this evaluation presents findings from over 6,500 outpatient administrations of mAb at services affiliated with a big healthcare group in the US.
Inside 48 hours of mAb infusion, 15.6% (1,043) of sufferers obtained a drug that was indicative of a potential response to the infusion; the vast majority of these had been gentle (e.g., acetaminophen). Roughly 5.2% of sufferers who obtained mAb (n=347) had a post-infusion emergency division go to or admission for COVID-19 illness development.
The outcomes of this evaluation point out that sufferers who obtain mAb have a low chance of each an instantaneous detrimental response to the remedy in addition to future inpatient admission associated to COVID-19 illness development.
A SARS-CoV-2 antibody broadly neutralizes SARS-related coronaviruses and variants by coordinated recognition of a virus-vulnerable web site
Potent neutralizing SARS-CoV-2 antibodies typically goal the spike protein receptor-binding web site (RBS), however the variability of RBS epitopes hampers broad neutralization of a number of sarbecoviruses and drifted viruses. Right here, utilizing humanized mice, we recognized an RBS antibody with a germline VH gene that potently neutralized SARS-related coronaviruses, together with SARS-CoV and SARS-CoV-2 variants.
X-ray crystallography revealed coordinated recognition by the heavy chain of non-RBS conserved websites and the sunshine chain of RBS with a binding angle mimicking the angiotensin-converting enzyme 2 (ACE2) receptor. The minimal footprints within the hypervariable area of RBS contributed to the breadth of neutralization, which was enhanced by immunoglobulin G3 (IgG3) class switching.
The coordinated binding resulted in broad neutralization of SARS-CoV and rising SARS-CoV-2 variants of concern. Low-dose therapeutic antibody remedy in hamsters lowered the virus titers and morbidity throughout SARS-CoV-2 problem. The structural foundation for broad neutralizing exercise could inform the design of a broad spectrum of therapeutics and vaccines.
Pharmacodynamic measures inside tumors expose differential exercise of PD(L)-1 antibody therapeutics
Macromolecules reminiscent of monoclonal antibodies (mAbs) are prone to expertise poor tumor penetration due to their massive dimension, and thus low drug publicity of goal cells inside a tumor might contribute to suboptimal responses. Given the problem of insufficient quantitative instruments to evaluate mAb exercise inside tumors, we hypothesized that measurement of accessible goal ranges in tumors might elucidate the pharmacologic exercise of a mAb and might be used to match the exercise of various mAbs.
Utilizing positron emission tomography (PET), we measured the pharmacodynamics of immune checkpoint protein programmed-death ligand 1 (PD-L1) to guage pharmacologic results of mAbs concentrating on PD-L1 and its receptor programmed cell demise protein 1 (PD-1). For PD-L1 quantification, we first developed a small peptide-based fluorine-18-labeled PET imaging agent, [18F]DK222, which supplied high-contrast pictures in preclinical fashions.
We then quantified accessible PD-L1 ranges within the tumor mattress throughout remedy with anti-PD-1 and anti-PD-L1 mAbs. Making use of mixed-effects fashions to those knowledge, we discovered delicate variations within the pharmacodynamic results of two anti-PD-1 mAbs (nivolumab and pembrolizumab).
In distinction, we noticed starkly divergent goal engagement with anti-PD-L1 mAbs (atezolizumab, avelumab, and durvalumab) that had been administered at equal doses, correlating with differential results on tumor development. Thus, we present that measuring PD-L1 pharmacodynamics informs mechanistic understanding of therapeutic mAbs concentrating on PD-L1 and PD-1.
These findings exhibit the worth of quantifying goal pharmacodynamics to elucidate the pharmacologic exercise of mAbs, unbiased of mAb biophysical properties and inclusive of all physiological variables, that are extremely heterogeneous inside and throughout tumors and sufferers.
Ehrlichia chaffeensis and E. canis hypothetical protein immunoanalysis reveals small secreted immunodominant proteins and conformation-dependent antibody epitopes
Immunomolecular characterization of Ehrlichia chaffeensis (E. ch.) and E. canis (E. ca.) has outlined protein orthologs, together with tandem repeat proteins (TRPs) which have immunodominant linear antibody epitopes. On this examine, we mixed bioinformatic evaluation and cell-free protein expression to determine undiscovered immunoreactive E. ch. and E. ca. hypothetical proteins.
Antigenicity of the E. ch. and E. ca. ORFeomes (n = 1105 and n = 925, respectively) was analyzed by the sequence-based prediction mannequin ANTIGENpro, and we recognized ~250 ORFs in every respective ORFeome as extremely antigenic. The hypothetical proteins (E. ch. n = 93 and E. ca. n = 98) current within the prime 250 antigenic ORFs had been additional investigated on this examine. By ELISA, 46 E. ch. and 30 E. ca.
IVTT-expressed hypothetical proteins reacted with antibodies in sera from naturally E. ch.-infected sufferers or E. ca.-infected canine. Furthermore, 15 E. ch. and 16 E. ca. proteins persistently reacted with a panel of sera from sufferers or canine, together with many that exposed the immunoreactivity of “gold commonplace” TRPs. Antibody epitopes in most (>70%) of those proteins exhibited partial or full conformation-dependence.
 Antibody) Cytokeratin 8 (Cytokeratin 8) Antibody |
|
20-abx009059 |
Abbexa |
-
EUR 360.00
-
EUR 526.80
-
EUR 226.80
|
|
|
|
 Antibody) Cytokeratin 7 (Cytokeratin 7) Antibody |
|
20-abx009060 |
Abbexa |
-
EUR 360.00
-
EUR 526.80
-
EUR 226.80
|
|
|
|
 Antibody) Cytokeratin 4 (Cytokeratin 4) Antibody |
|
20-abx121076 |
Abbexa |
-
EUR 360.00
-
EUR 526.80
-
EUR 226.80
|
|
|
|
 Antibody) Cytokeratin 14 (Cytokeratin 14) Antibody |
|
20-abx121588 |
Abbexa |
-
EUR 360.00
-
EUR 526.80
-
EUR 226.80
|
|
|
|
Cytokeratin 8 (Cytokeratin 8) Antibody |
|
abx010621-100ul |
Abbexa |
100 ul |
EUR 493.2 |
|
|
 Antibody) Cytokeratin 15 (Cytokeratin 15) Antibody |
|
20-abx225265 |
Abbexa |
-
EUR 444.00
-
EUR 727.20
-
EUR 376.80
|
|
|
|
Cytokeratin 14 (Cytokeratin 14) Antibody |
|
abx232195-100ug |
Abbexa |
100 ug |
EUR 577.2 |
|
|
Cytokeratin 14 (Cytokeratin 14) Antibody |
|
abx232196-100ug |
Abbexa |
100 ug |
EUR 610.8 |
|
|
Cytokeratin 14 (Cytokeratin 14) Antibody |
|
abx232197-100ug |
Abbexa |
100 ug |
EUR 661.2 |
|
|
Cytokeratin 15 (Cytokeratin 15) Antibody |
|
abx232198-100ug |
Abbexa |
100 ug |
EUR 577.2 |
|
|
Cytokeratin 15 (Cytokeratin 15) Antibody |
|
abx232199-100ug |
Abbexa |
100 ug |
EUR 610.8 |
|
|
Cytokeratin 4 (Cytokeratin 4) Antibody |
|
abx232214-100ug |
Abbexa |
100 ug |
EUR 577.2 |
|
|
Cytokeratin 7 (Cytokeratin 7) Antibody |
|
abx232217-100ug |
Abbexa |
100 ug |
EUR 610.8 |
|
|
Cytokeratin 7 (Cytokeratin 7) Antibody |
|
abx232218-100ug |
Abbexa |
100 ug |
EUR 661.2 |
|
|
Cytokeratin 8 (Cytokeratin 8) Antibody |
|
abx232221-100ug |
Abbexa |
100 ug |
EUR 577.2 |
|
|
Cytokeratin 8 (Cytokeratin 8) Antibody |
|
abx232222-100ug |
Abbexa |
100 ug |
EUR 661.2 |
|
|
Cytokeratin 8 (Cytokeratin 8) Antibody |
|
abx232223-100ug |
Abbexa |
100 ug |
EUR 661.2 |
|
|
 Antibody (FITC)) Cytokeratin 8 (Cytokeratin 8) Antibody (FITC) |
|
abx139679-01mg |
Abbexa |
0.1 mg |
EUR 510 |
|
|
 Cytokeratin antibody |
|
20R-CP006 |
Fitzgerald |
100 uL |
EUR 550.8 |
|
Description: Guinea Pig polyclonal Cytokeratin antibody |
Cytokeratin antibody |
|
10R-6655 |
Fitzgerald |
100 ug |
EUR 625.2 |
|
Description: Mouse monoclonal Cytokeratin antibody |
Cytokeratin antibody |
|
10R-6656 |
Fitzgerald |
100 ug |
EUR 625.2 |
|
Description: Mouse monoclonal Cytokeratin antibody |
 Cytokeratin 13 antibody |
|
70R-1178 |
Fitzgerald |
100 ug |
EUR 452.4 |
|
Description: Rabbit polyclonal Cytokeratin 13 antibody raised against the C terminal of KRT13 |
 Cytokeratin 20 antibody |
|
70R-1189 |
Fitzgerald |
100 ug |
EUR 452.4 |
|
Description: Rabbit polyclonal Cytokeratin 20 antibody raised against the middle region of KRT20 |
 Cytokeratin 2 antibody |
|
70R-12684 |
Fitzgerald |
100 ul |
EUR 548.4 |
|
Description: Affinity purified Rabbit polyclonal Cytokeratin 2 antibody |
 Cytokeratin 19 antibody |
|
10-1210 |
Fitzgerald |
500 ug |
EUR 522 |
|
Description: Mouse monoclonal Cytokeratin 19 antibody |
 cytokeratin 20 Peptide |
|
43-166P |
ProSci |
0.1 mg |
EUR 405.6 |
cytokeratin 20 Peptide |
|
43-167P |
ProSci |
0.1 mg |
EUR 405.6 |
 cytokeratin 19 Peptide |
|
43-484P |
ProSci |
0.1 mg |
EUR 405.6 |
cytokeratin 19 Peptide |
|
43-491P |
ProSci |
0.1 mg |
EUR 405.6 |
 Cytokeratin 1 antibody |
|
70R-4604 |
Fitzgerald |
50 ug |
EUR 560.4 |
|
Description: Rabbit polyclonal Cytokeratin 1 antibody |
 Cytokeratin 5 antibody |
|
70R-49975 |
Fitzgerald |
100 ul |
EUR 292.8 |
|
Description: Purified Polyclonal Cytokeratin 5 antibody |
 Cytokeratin 7 antibody |
|
70R-49976 |
Fitzgerald |
100 ul |
EUR 292.8 |
|
Description: Purified Polyclonal Cytokeratin 7 antibody |
 Cytokeratin 8 antibody |
|
70R-49977 |
Fitzgerald |
100 ul |
EUR 344.4 |
|
Description: Purified Polyclonal Cytokeratin 8 antibody |
Cytokeratin 8 antibody |
|
70R-49978 |
Fitzgerald |
100 ul |
EUR 292.8 |
|
Description: Purified Polyclonal Cytokeratin 8 antibody |
 Cytokeratin 10 antibody |
|
70R-49979 |
Fitzgerald |
100 ul |
EUR 292.8 |
|
Description: Purified Polyclonal Cytokeratin 10 antibody |
Cytokeratin 13 antibody |
|
70R-49980 |
Fitzgerald |
100 ul |
EUR 292.8 |
|
Description: Purified Polyclonal Cytokeratin 13 antibody |
 Cytokeratin 14 antibody |
|
70R-49981 |
Fitzgerald |
100 ul |
EUR 292.8 |
|
Description: Purified Polyclonal Cytokeratin 14 antibody |
 Cytokeratin 16 antibody |
|
70R-49982 |
Fitzgerald |
100 ul |
EUR 292.8 |
|
Description: Purified Polyclonal Cytokeratin 16 antibody |
 Cytokeratin 17 antibody |
|
70R-49983 |
Fitzgerald |
100 ul |
EUR 292.8 |
|
Description: Purified Polyclonal Cytokeratin 17 antibody |
 Cytokeratin 18 antibody |
|
70R-49984 |
Fitzgerald |
100 ul |
EUR 344.4 |
|
Description: Purified Polyclonal Cytokeratin 18 antibody |
Cytokeratin 18 antibody |
|
70R-49985 |
Fitzgerald |
100 ul |
EUR 292.8 |
|
Description: Purified Polyclonal Cytokeratin 18 antibody |
Cytokeratin 19 antibody |
|
70R-49986 |
Fitzgerald |
100 ul |
EUR 292.8 |
|
Description: Purified Polyclonal Cytokeratin 19 antibody |
Cytokeratin 19 antibody |
|
70R-49987 |
Fitzgerald |
100 ul |
EUR 292.8 |
|
Description: Purified Polyclonal Cytokeratin 19 antibody |
 Cytokeratin 84 antibody |
|
70R-49988 |
Fitzgerald |
100 ul |
EUR 292.8 |
|
Description: Purified Polyclonal Cytokeratin 84 antibody |
Cytokeratin 10 antibody |
|
70R-2225 |
Fitzgerald |
50 ug |
EUR 560.4 |
|
Description: Rabbit polyclonal Cytokeratin 10 antibody |
Cytokeratin 13 antibody |
|
70R-2265 |
Fitzgerald |
50 ug |
EUR 560.4 |
|
Description: Rabbit polyclonal Cytokeratin 13 antibody raised against the N terminal of KRT13 |
Cytokeratin 16 antibody |
|
70R-2869 |
Fitzgerald |
50 ug |
EUR 560.4 |
|
Description: Rabbit polyclonal Cytokeratin 16 antibody |
Cytokeratin 16 antibody |
|
70R-2870 |
Fitzgerald |
50 ug |
EUR 560.4 |
|
Description: Rabbit polyclonal Cytokeratin 16 antibody |
Cytokeratin 7 antibody |
|
70R-2930 |
Fitzgerald |
50 ug |
EUR 560.4 |
|
Description: Rabbit polyclonal Cytokeratin 7 antibody raised against the N terminal of KRT7 |
Cytokeratin 19 antibody |
|
70R-2947 |
Fitzgerald |
50 ug |
EUR 560.4 |
|
Description: Rabbit polyclonal Cytokeratin 19 antibody raised against the N terminal of KRT19 |
 Cytokeratin 23 antibody |
|
70R-2948 |
Fitzgerald |
50 ug |
EUR 560.4 |
|
Description: Rabbit polyclonal Cytokeratin 23 antibody |
 Cytokeratin 24 antibody |
|
70R-2986 |
Fitzgerald |
50 ug |
EUR 560.4 |
|
Description: Rabbit polyclonal Cytokeratin 24 antibody raised against the middle region of KRT24 |
Cytokeratin 84 antibody |
|
70R-3002 |
Fitzgerald |
50 ug |
EUR 560.4 |
|
Description: Rabbit polyclonal Cytokeratin 84 antibody raised against the middle region of KRT84 |
Cytokeratin 19 antibody |
|
70R-3035 |
Fitzgerald |
50 ug |
EUR 560.4 |
|
Description: Rabbit polyclonal Cytokeratin 19 antibody raised against the N terminal of KRT19 |
 Cytokeratin 75 antibody |
|
70R-3038 |
Fitzgerald |
50 ug |
EUR 560.4 |
|
Description: Rabbit polyclonal Cytokeratin 75 antibody raised against the N terminal of KRT75 |
Cytokeratin 75 antibody |
|
70R-3039 |
Fitzgerald |
50 ug |
EUR 560.4 |
|
Description: Rabbit polyclonal Cytokeratin 75 antibody raised against the middle region of KRT75 |
Cytokeratin 5 antibody |
|
70R-35563 |
Fitzgerald |
100 ug |
EUR 418.8 |
|
Description: Purified Rabbit polyclonal Cytokeratin 5 antibody |
Cytokeratin 17 antibody |
|
70R-3229 |
Fitzgerald |
50 ug |
EUR 560.4 |
|
Description: Rabbit polyclonal Cytokeratin 17 antibody raised against the C terminal of KRT17 |
Cytokeratin 8 antibody |
|
70R-3263 |
Fitzgerald |
50 ug |
EUR 560.4 |
|
Description: Rabbit polyclonal Cytokeratin 8 antibody raised against the middle region of KRT8 |
Cytokeratin 8 antibody |
|
70R-3292 |
Fitzgerald |
50 ug |
EUR 560.4 |
|
Description: Rabbit polyclonal Cytokeratin 8 antibody raised against the N terminal of KRT8 |
Cytokeratin 18 antibody |
|
70R-33530 |
Fitzgerald |
100 ug |
EUR 392.4 |
|
Description: Rabbit polyclonal Cytokeratin 18 antibody |
Cytokeratin 8 antibody |
|
70R-33532 |
Fitzgerald |
100 ug |
EUR 392.4 |
|
Description: Rabbit polyclonal Cytokeratin 8 antibody |
Cytokeratin 18 antibody |
|
70R-1405 |
Fitzgerald |
100 ug |
EUR 452.4 |
|
Description: Rabbit polyclonal Cytokeratin 18 antibody raised against the C terminal of KRT18 |
Cytokeratin 18 antibody |
|
70R-1474 |
Fitzgerald |
100 ug |
EUR 452.4 |
|
Description: Rabbit polyclonal Cytokeratin 18 antibody raised against the N terminal of KRT18 |
Cytokeratin 8 antibody |
|
70R-51570 |
Fitzgerald |
100 ul |
EUR 292.8 |
|
Description: Purified Polyclonal Cytokeratin 8 antibody |
Cytokeratin 8 antibody |
|
70R-51571 |
Fitzgerald |
100 ul |
EUR 292.8 |
|
Description: Purified Polyclonal Cytokeratin 8 antibody |
Cytokeratin 18 antibody |
|
70R-51572 |
Fitzgerald |
100 ul |
EUR 344.4 |
|
Description: Purified Polyclonal Cytokeratin 18 antibody |
Cytokeratin 18 antibody |
|
70R-51573 |
Fitzgerald |
100 ul |
EUR 292.8 |
|
Description: Purified Polyclonal Cytokeratin 18 antibody |
Cytokeratin 10 antibody |
|
70R-13235 |
Fitzgerald |
100 ul |
EUR 516 |
|
Description: Affinity purified Rabbit polyclonal Cytokeratin 10 antibody |
Cytokeratin 13 antibody |
|
70R-13317 |
Fitzgerald |
100 ul |
EUR 548.4 |
|
Description: Affinity purified Rabbit polyclonal Cytokeratin 13 antibody |
Cytokeratin 20 antibody |
|
70R-13379 |
Fitzgerald |
100 ul |
EUR 548.4 |
|
Description: Affinity purified Rabbit polyclonal Cytokeratin 20 antibody |
 Cytokeratin 34 antibody |
|
70R-13483 |
Fitzgerald |
100 ul |
EUR 548.4 |
|
Description: Affinity purified Rabbit polyclonal Cytokeratin 34 antibody |
 Cytokeratin 31 antibody |
|
70R-13495 |
Fitzgerald |
100 ul |
EUR 548.4 |
|
Description: Affinity purified Rabbit polyclonal Cytokeratin 31 antibody |
Cytokeratin 8 antibody |
|
70R-13833 |
Fitzgerald |
100 ug |
EUR 386.4 |
|
Description: Affinity purified Rabbit polyclonal Cytokeratin 8 antibody |
Cytokeratin 19 antibody |
|
70R-13877 |
Fitzgerald |
100 ug |
EUR 386.4 |
|
Description: Affinity purified Rabbit polyclonal Cytokeratin 19 antibody |
 Cytokeratin 5 Antibody |
|
39247-100ul |
SAB |
100ul |
EUR 468 |
 Cytokeratin-1 Antibody |
|
39339-100ul |
SAB |
100ul |
EUR 468 |
 Cytokeratin-7 Antibody |
|
48356-100ul |
SAB |
100ul |
EUR 399.6 |
Cytokeratin-7 Antibody |
|
48356-50ul |
SAB |
50ul |
EUR 286.8 |
 Cytokeratin 19 Antibody |
|
48622-100ul |
SAB |
100ul |
EUR 399.6 |
Cytokeratin 19 Antibody |
|
48622-50ul |
SAB |
50ul |
EUR 286.8 |
 Cytokeratin 20 Antibody |
|
48624-100ul |
SAB |
100ul |
EUR 399.6 |
Cytokeratin 20 Antibody |
|
48624-50ul |
SAB |
50ul |
EUR 286.8 |
 Cytokeratin 17 Antibody |
|
48633-100ul |
SAB |
100ul |
EUR 399.6 |
Cytokeratin 17 Antibody |
|
48633-50ul |
SAB |
50ul |
EUR 286.8 |
 Cytokeratin 18 Antibody |
|
48696-100ul |
SAB |
100ul |
EUR 399.6 |
Cytokeratin 18 Antibody |
|
48696-50ul |
SAB |
50ul |
EUR 286.8 |
Cytokeratin 5 Antibody |
|
48720-100ul |
SAB |
100ul |
EUR 399.6 |
Cytokeratin 5 Antibody |
|
48720-50ul |
SAB |
50ul |
EUR 286.8 |
 Cytokeratin 15 Antibody |
|
48891-100ul |
SAB |
100ul |
EUR 399.6 |
Cytokeratin 15 Antibody |
|
48891-50ul |
SAB |
50ul |
EUR 286.8 |
 Cytokeratin 7 Antibody |
|
48899-100ul |
SAB |
100ul |
EUR 399.6 |
Cytokeratin 7 Antibody |
|
48899-50ul |
SAB |
50ul |
EUR 286.8 |
 Cytokeratin 10 Antibody |
|
48912-100ul |
SAB |
100ul |
EUR 399.6 |
Cytokeratin 10 Antibody |
|
48912-50ul |
SAB |
50ul |
EUR 286.8 |
 Cytokeratin 16 Antibody |
|
48928-100ul |
SAB |
100ul |
EUR 399.6 |
Cytokeratin 16 Antibody |
|
48928-50ul |
SAB |
50ul |
EUR 286.8 |
 Cytokeratin 14 Antibody |
|
48956-100ul |
SAB |
100ul |
EUR 399.6 |
Cytokeratin 14 Antibody |
|
48956-50ul |
SAB |
50ul |
EUR 286.8 |
Cytokeratin 5 Antibody |
|
48957-100ul |
SAB |
100ul |
EUR 399.6 |
Cytokeratin 5 Antibody |
|
48957-50ul |
SAB |
50ul |
EUR 286.8 |
 Cytokeratin 1 Antibody |
|
49059-100ul |
SAB |
100ul |
EUR 399.6 |
Cytokeratin 1 Antibody |
|
49059-50ul |
SAB |
50ul |
EUR 286.8 |
 Cytokeratin 13 Antibody |
|
49069-100ul |
SAB |
100ul |
EUR 399.6 |
Cytokeratin 13 Antibody |
|
49069-50ul |
SAB |
50ul |
EUR 286.8 |
 Cytokeratin 6 Antibody |
|
49086-100ul |
SAB |
100ul |
EUR 399.6 |
Cytokeratin 6 Antibody |
|
49086-50ul |
SAB |
50ul |
EUR 286.8 |
 Cytokeratin 4 Antibody |
|
49087-100ul |
SAB |
100ul |
EUR 399.6 |
Cytokeratin 4 Antibody |
|
49087-50ul |
SAB |
50ul |
EUR 286.8 |
Cytokeratin 4 Antibody |
|
49108-100ul |
SAB |
100ul |
EUR 399.6 |
Cytokeratin 4 Antibody |
|
49108-50ul |
SAB |
50ul |
EUR 286.8 |
 Cytokeratin 9 Antibody |
|
49191-100ul |
SAB |
100ul |
EUR 399.6 |
Cytokeratin 9 Antibody |
|
49191-50ul |
SAB |
50ul |
EUR 286.8 |
 Cytokeratin 2e Antibody |
|
49220-100ul |
SAB |
100ul |
EUR 399.6 |
Cytokeratin 2e Antibody |
|
49220-50ul |
SAB |
50ul |
EUR 286.8 |
Cytokeratin 19 Antibody |
|
45016-100ul |
SAB |
100ul |
EUR 302.4 |
Cytokeratin 19 Antibody |
|
45016-50ul |
SAB |
50ul |
EUR 224.4 |
Cytokeratin 14 antibody |
|
20R-CP002 |
Fitzgerald |
100 ul |
EUR 676.8 |
|
Description: Guinea Pig polyclonal Cytokeratin 14 antibody |
Cytokeratin 5 antibody |
|
20R-CP003 |
Fitzgerald |
100 uL |
EUR 654 |
|
Description: Guinea Pig polyclonal Cytokeratin 5 antibody |
 Cytokeratin 18 protein |
|
30R-AC039 |
Fitzgerald |
250 ug |
EUR 817.2 |
|
Description: Purified recombinant Human Cytokeratin 18 protein |
 Cytokeratin 19 protein |
|
30R-AC040 |
Fitzgerald |
100 ug |
EUR 495.6 |
|
Description: Purified recombinant Human Cytokeratin 19 protein |
 Cytokeratin 8 protein |
|
30R-AC041 |
Fitzgerald |
100 ug |
EUR 501.6 |
|
Description: Purified recombinant Human Cytokeratin 8 protein |
Cytokeratin 19 antibody |
|
10R-6759 |
Fitzgerald |
1 ml |
EUR 482.4 |
|
Description: Mouse monoclonal Cytokeratin 19 antibody |
Cytokeratin 18 antibody |
|
10R-6766 |
Fitzgerald |
1 ml |
EUR 482.4 |
|
Description: Mouse monoclonal Cytokeratin 18 antibody |
 Cytokeratin AE1 antibody |
|
10R-6767 |
Fitzgerald |
1 ml |
EUR 508.8 |
|
Description: Mouse monoclonal Cytokeratin AE1 antibody |
 Cytokeratin AE3 antibody |
|
10R-6768 |
Fitzgerald |
1 ml |
EUR 493.2 |
|
Description: Mouse monoclonal Cytokeratin AE3 antibody |
 Cytokeratin antibody cocktail |
|
10R-6769 |
Fitzgerald |
1 ml |
EUR 672 |
|
Description: Mouse monoclonal Cytokeratin antibody cocktail |
Cytokeratin 7 antibody |
|
10R-7842 |
Fitzgerald |
100 ug |
EUR 386.4 |
|
Description: Mouse monoclonal Cytokeratin 7 antibody |
Cytokeratin 18 antibody |
|
10R-7844 |
Fitzgerald |
100 ug |
EUR 366 |
|
Description: Mouse monoclonal Cytokeratin 18 antibody |
 Cytokeratin 4 antibody |
|
10R-7960 |
Fitzgerald |
100 ug |
EUR 457.2 |
|
Description: Mouse monoclonal Cytokeratin 4 antibody |
Cytokeratin 7 antibody |
|
10R-7962 |
Fitzgerald |
100 ug |
EUR 444 |
|
Description: Mouse monoclonal Cytokeratin 7 antibody |
Cytokeratin 7 antibody |
|
10R-7963 |
Fitzgerald |
100 ug |
EUR 457.2 |
|
Description: Mouse monoclonal Cytokeratin 7 antibody |
Cytokeratin 8 antibody |
|
10R-7964 |
Fitzgerald |
100 ug |
EUR 444 |
|
Description: Mouse monoclonal Cytokeratin 8 antibody |
Cytokeratin 8 antibody |
|
10R-7965 |
Fitzgerald |
100 ug |
EUR 444 |
|
Description: Mouse monoclonal Cytokeratin 8 antibody |
Cytokeratin 10 antibody |
|
10R-7966 |
Fitzgerald |
100 ug |
EUR 444 |
|
Description: Mouse monoclonal Cytokeratin 10 antibody |
Cytokeratin 10 antibody |
|
10R-7967 |
Fitzgerald |
100 ug |
EUR 457.2 |
|
Description: Mouse monoclonal Cytokeratin 10 antibody |
Cytokeratin 13 antibody |
|
10R-7969 |
Fitzgerald |
100 ug |
EUR 457.2 |
|
Description: Mouse monoclonal Cytokeratin 13 antibody |
Cytokeratin 14 antibody |
|
10R-7970 |
Fitzgerald |
100 ug |
EUR 444 |
|
Description: Mouse monoclonal Cytokeratin 14 antibody |
Cytokeratin 17 antibody |
|
10R-7971 |
Fitzgerald |
100 ug |
EUR 457.2 |
|
Description: Mouse monoclonal Cytokeratin 17 antibody |
Cytokeratin 18 antibody |
|
10R-7972 |
Fitzgerald |
100 ug |
EUR 444 |
|
Description: Mouse monoclonal Cytokeratin 18 antibody |
Cytokeratin 18 antibody |
|
10R-7973 |
Fitzgerald |
100 ug |
EUR 444 |
|
Description: Mouse monoclonal Cytokeratin 18 antibody |
Cytokeratin 18 antibody |
|
10R-7974 |
Fitzgerald |
100 ug |
EUR 457.2 |
|
Description: Mouse monoclonal Cytokeratin 18 antibody |
Cytokeratin 19 antibody |
|
10R-7975 |
Fitzgerald |
100 ug |
EUR 444 |
|
Description: Mouse monoclonal Cytokeratin 19 antibody |
 Cytokeratin 6 antibody |
|
10R-7978 |
Fitzgerald |
100 ug |
EUR 457.2 |
|
Description: Mouse monoclonal Cytokeratin 6 antibody |
The bulk (23/31; 74%) of the most important immunoreactive proteins recognized had been small (≤250 aa), and 20/31 (65%) had been predicted to be secreted effectors. Not like the robust linear antibody epitopes beforehand recognized in TRP and OMP orthologs, there have been contrasting variations within the E. ch. and E. ca. antigenic repertoires, epitopes and ortholog immunoreactivity. This examine reveals quite a few beforehand undefined immunodominant and subdominant antigens, and illustrates the breadth, complexity, and variety of immunoreactive proteins/epitopes in Ehrlichia.
